SURMODICS INC (SRDX) Stock News

Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mentions: BSX

Are Options Traders Betting on a Big Move in Surmodics Stock?

Investors need to pay close attention to SRDX stock based on the movements in the options market lately.

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

Mentions: BSX ITGR EHC

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

Earnings Scheduled For April 30, 2025

Mentions: AVB CMPR PPL LANC ...

A Look at Surmodics's Upcoming Earnings Report

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surmodics (NASDAQ:SRDX) just reported results for the third quarter of 2024.Sur...

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024

SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders

Mentions: ATRI AGS VAPO

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders

Mentions: ALIM ATRI

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)

Mentions: MRO ATRI AKLI COP